Business Description
Biogen Inc
NAICS : 325412
SIC : 2834
ISIN : ARBCOM4601A8
Share Class Description:
BUE:BIIB: CedearTotal Employee Number:
7,500Compare
Compare
Traded in other countries / regions
BIIB.USABIIB.Argentina0R1B.UKBIIB.MexicoIDP.GermanyBIIB34.BrazilBIIB.Austria1BIIB.ItalyBIIB_KZ.KazakhstanBIIB.SwitzerlandBIIB.Chile IPO Date
2019-03-07Description
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.65 | |||||
Equity-to-Asset | 0.63 | |||||
Debt-to-Equity | 0.35 | |||||
Debt-to-EBITDA | 2.43 | |||||
Interest Coverage | 8.37 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 3.36 | |||||
Beneish M-Score | -2.68 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -1.2 | |||||
3-Year EBITDA Growth Rate | -16 | |||||
3-Year EPS without NRI Growth Rate | -4.7 | |||||
3-Year FCF Growth Rate | 19.6 | |||||
3-Year Book Growth Rate | 10.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 7.1 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 1.85 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 31.31 | |||||
9-Day RSI | 38.59 | |||||
14-Day RSI | 43.53 | |||||
3-1 Month Momentum % | 13.33 | |||||
6-1 Month Momentum % | 14.91 | |||||
12-1 Month Momentum % | 73.61 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.06 | |||||
Quick Ratio | 2.41 | |||||
Cash Ratio | 1.43 | |||||
Days Inventory | 325.9 | |||||
Days Sales Outstanding | 70.43 | |||||
Days Payable | 60.04 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.6 | |||||
Shareholder Yield % | 0.21 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 75.49 | |||||
Operating Margin % | 23.18 | |||||
Net Margin % | 13.81 | |||||
EBITDA Margin % | 27.16 | |||||
FCF Margin % | 23.83 | |||||
OCF Margin % | 26.69 | |||||
ROE % | 7.64 | |||||
ROA % | 4.75 | |||||
ROIC % | 8.65 | |||||
3-Year ROIIC % | -6.64 | |||||
ROC (Joel Greenblatt) % | 36.76 | |||||
ROCE % | 7.51 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 7 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 20.6 | |||||
Forward PE Ratio | 1.19 | |||||
PE Ratio without NRI | 12.12 | |||||
Shiller PE Ratio | 9.56 | |||||
Price-to-Owner-Earnings | 19.28 | |||||
PS Ratio | 2.85 | |||||
PB Ratio | 1.52 | |||||
Price-to-Tangible-Book | 9.11 | |||||
Price-to-Free-Cash-Flow | 12.23 | |||||
Price-to-Operating-Cash-Flow | 10.93 | |||||
EV-to-EBIT | 16.13 | |||||
EV-to-Forward-EBIT | 16.1 | |||||
EV-to-EBITDA | 11.34 | |||||
EV-to-Forward-EBITDA | 10.54 | |||||
EV-to-Revenue | 3.08 | |||||
EV-to-Forward-Revenue | 3.07 | |||||
EV-to-FCF | 13.22 | |||||
Price-to-GF-Value | 1 | |||||
Price-to-Projected-FCF | 0.77 | |||||
Price-to-Median-PS-Value | 0.78 | |||||
Price-to-Graham-Number | 2.22 | |||||
Earnings Yield (Greenblatt) % | 6.2 | |||||
FCF Yield % | 8.17 | |||||
Forward Rate of Return (Yacktman) % | 0.05 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Biogen Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ARS) | 13,356,075.169 | ||
| EPS (TTM) (ARS) | 11972.855 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | 0.75 | ||
| 3-Year Sortino Ratio | 1.39 | ||
| Volatility % | 28.38 | ||
| 14-Day RSI | 43.53 | ||
| 14-Day ATR (ARS) | 893.964994 | ||
| 20-Day SMA (ARS) | 24541 | ||
| 12-1 Month Momentum % | 73.61 | ||
| 52-Week Range (ARS) | 12050 - 27080 | ||
| Shares Outstanding (Mil) | 147.64 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Biogen Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Biogen Inc Stock Events
| Event | Date | Price (ARS) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-30 08:30 | In 108 days | ||
| Third quarter earnings results for 2026 | 2026-10-30 | In 107 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-31 08:30 | In 17 days | ||
| Second quarter earnings results for 2026 | 2026-07-31 | In 16 days | ||
| General meeting for 2026 | 2026-06-09 09:00 | 22,480.00 (-1.92%) | ||
| First quarter earnings conference call for 2026 | 2026-04-29 08:00 | 21,130.00 (-1.17%) | ||
| First quarter earnings results for 2026 | 2026-04-29 | 21,130.00 (-1.17%) | ||
| Biogen Business Update Webcast | 2026-03-31 08:30 | 21,370.00 (+1.28%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-06 08:30 | 21,410.00 (+0.19%) | ||
| Annual report for 2025 | 2026-02-06 | 21,410.00 (+0.19%) |
Show
Entries
Biogen Inc Frequently Asked Questions
What is Biogen Inc(BUE:BIIB)'s stock price today?
The current price of BUE:BIIB is ARS23010.00. The 52 week high of BUE:BIIB is ARS27080.00 and 52 week low is ARS12050.00.
When is next earnings date of Biogen Inc(BUE:BIIB)?
The next earnings date of Biogen Inc(BUE:BIIB) is 2026-07-31 Est..
Does Biogen Inc(BUE:BIIB) pay dividends? If so, how much?
Biogen Inc(BUE:BIIB) does not pay dividend.
Press Release
Articles on Biogen Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers